Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimisation of Treatment in Patients with CRSwNP. an RCT of Mepolizumab and Surgical Treatment with FESS and Mepolizumab Versus Only Mepolizumab Over a 6- and 12-month Follow-up

NCT05598814 is registered in ClinicalTrials.gov with Vibeke Backer as lead sponsor.

NCT NCT05598814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05598814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimisation of Treatment in Patients with CRSwNP. an RCT of Mepolizumab and Surgical Treatment with FESS and Mepolizumab Versus Only Mepolizumab Over a 6- and 12-month Follow-up
Lead sponsor
Vibeke Backer
Phase
Phase 4
Overall status
Active, not recruiting
Start date
April 1, 2023
Completion date
August 31, 2025
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic rhinosinusitis with nasal polyps